Fusion

J.P. Morgan Enhances Data Management Capabilities for Securities Services Clients

Retrieved on: 
Tuesday, October 10, 2023
Professional Services, Data Analytics, Technology, Software, Finance, Artificial Intelligence, Banking, Cloud, Investment, Machine learning, Android SDK, AI, Data mesh, Organization, Elasticity, Project Jupyter, Electron capture, J. P. Morgan, Growth, Public sector banks in India, Java, REST, API, Security (finance), Cryptocurrency, Video game, Python, Snowflake, Fusion

J.P. Morgan today announced the launch of its Securities Services Data Mesh for institutional investors, available through Fusion by J.P. Morgan (Fusion).

Key Points: 
  • J.P. Morgan today announced the launch of its Securities Services Data Mesh for institutional investors, available through Fusion by J.P. Morgan (Fusion).
  • Fusion supports investors in this journey with the release of the Data Mesh, which now includes Securities Services data for the first time.
  • Morgan’s Fusion platform is transforming the client experience by modernizing how their clients access Securities Services data and analytics, fueled by the power, scale and secure data sharing of the Snowflake Financial Services Data Cloud,” said Benoit Dageville, Snowflake Co-Founder and President of Products.
  • Tim Fitzgerald, Global Head of Securities Services, J.P. Morgan said, “The Securities Services industry has become increasingly data-driven.

Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors

Retrieved on: 
Monday, October 16, 2023
B.A, University of Virginia Darden School of Business, MIT Sloan School of Management, Acquisition, Business, Novartis, Pharmaceutical Research and Manufacturers of America, BMS, PSMA, Medication, Boston Consulting Group, Therapy, Doctor of Philosophy, Gilead Sciences, Biology, Oslo-Fergene, Corporate development, Sutro Biopharma, University, Corporation, Stanford University, Cancer, Bristol Myers Squibb, University of Colorado Student Government, Investment, Senior, Mirati Therapeutics, Wellesley College, TAT, Independent Board for Presbyterian Foreign Missions, Immunology, Mobil, United States of Europe, Canada, Patient, Management, Oncology, Fusion, Ipsen, Microbiology

Dr. Bender, Ms. Bitetti and Mr. Meek succeed Johan Christenson, Ph.D., Chau Khuong and Heather Preston, M.D., who will step down from Fusion's Board effective today.

Key Points: 
  • Dr. Bender, Ms. Bitetti and Mr. Meek succeed Johan Christenson, Ph.D., Chau Khuong and Heather Preston, M.D., who will step down from Fusion's Board effective today.
  • Dr. Jeremy Bender is currently Chief Executive Officer of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on pediatric cancer.
  • Mr. David Meek most recently served as Chief Executive Officer and Member of the Board of Directors of Mirati Therapeutics.
  • He currently serves on the Board of Directors of uniQure N.V. and previously served on the Board of Directors of Entasis Therapeutics (acquired by Innoviva).

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

AnChain.AI and BlockTrace Join Forces to Provide Cutting Edge Solutions to National Security Sector Partners

Retrieved on: 
Tuesday, October 10, 2023
Partnership, Knowledge, Intelligence, Government, Digital asset, Innovative Solutions In Space, Organization, Decentralized finance, Naval Criminal Investigative Service, Ecosystem, Law enforcement, Generative, Synthetic media, Public sector, Financial institution, LLM, Fusion, Cryptocurrency

SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- AnChain.AI, the world's first company delivering Generative AI, LLM, and GPT-powered solutions for investigating Smart Contract Web3 Digital Assets, and BlockTrace, the leading digital assets, cyber intelligence and integrations firm, today announced a new partnership to deliver cutting-edge solutions to national security sector partners engaged in the fight against crypto-related crime to address national security challenges. With the proliferation of decentralized finance (DeFi) and blockchain-based applications, the need for national security focused institutions to partner with companies that offer unique expertise has never been more important.

Key Points: 
  • With the proliferation of decentralized finance (DeFi) and blockchain-based applications, the need for national security focused institutions to partner with companies that offer unique expertise has never been more important.
  • Additionally, state and non-state actors continue to abuse this ecosystem in ways that threaten national security priorities.
  • AnChain.AI and BlockTrace share a commitment to helping national security agencies build a safer DeFi ecosystem with the tools and knowledge to address the increasingly complex challenges posed by smart contracts and cybercrime.
  • Furthermore, BlockTrace is in a unique position to integrate custom cyber data solutions at facilities focused on national security which require a government security clearance.

Krylon® Announces 2024 Color of the Year: Bluebird

Retrieved on: 
Monday, October 2, 2023
Residential Building & Real Estate, Manufacturing, Construction & Property, Interior Design, Women, Men, Retail, Home Goods, Consumer, Other Construction & Property, Chemicals, Plastics, Fusion, Multimedia, DIY, Wood, Nature, Personality, System, Glass, Sand, Interior design, Paint, Sherwin-Williams, Bluebird

A contemporary shade that evokes a profound connection to serene blue spaces found in nature, Bluebird is Krylon’s 2024 Color of the Year.

Key Points: 
  • A contemporary shade that evokes a profound connection to serene blue spaces found in nature, Bluebird is Krylon’s 2024 Color of the Year.
  • View the full release here: https://www.businesswire.com/news/home/20231002587193/en/
    A contemporary shade that evokes a profound connection to serene blue spaces found in nature, Bluebird is Krylon’s 2024 Color of the Year.
  • (Photo: Business Wire)
    “Bluebird evokes joy and contentment within a space, embracing consumer desire for ‘dopamine décor’,” said Ashley Banbury, Krylon's Color Marketing Manager.
  • Krylon's selection of Bluebird as the 2024 Color of the Year reinforces its dedication to offering innovative and inspiring design solutions that resonate with consumers.

Sisense Unveils Public Preview of Compose SDK for Fusion, Empowering Developers to Build Insights-Driven Products

Retrieved on: 
Thursday, September 28, 2023
Data Analytics, Data Management, Professional Services, Technology, Software, Sophos, Composability, Maintenance, Software as a service, UI, API, Fusion, Composition, Creativity, Organization, Documentation, Engineering, Entrepreneurship, Magic Quadrant, Library, SDK, 3D printing, Industrial design, Gartner, Sisense, Hive

Sisense , an analytics platform provider that empowers thousands of companies to build and embed analytics into data products, today unveiled the public preview of Compose SDK for Fusion .

Key Points: 
  • Sisense , an analytics platform provider that empowers thousands of companies to build and embed analytics into data products, today unveiled the public preview of Compose SDK for Fusion .
  • "We believe that this new era of composable modern apps is fundamentally changing how applications are developed and delivered.
  • “Compose SDK for Fusion accelerates time to value with a modular, flexible, API-first approach built on the foundation of a complete componentized architecture.
  • For more information about Compose SDK for Fusion and Sisense, please visit Sisense.com .

Fusion Fuel Receives Purchase Order for 300 kW Electrolyzer and Balance of Plant System from Leading Global Building Solutions Supplier

Retrieved on: 
Wednesday, September 27, 2023
Oxygen, PEM, Fusion, Electrolysis, Water, Hydrogen, Renewable energy

The client has placed a purchase order for a 300 kW PEM electrolyzer and associated balance of plant equipment.

Key Points: 
  • The client has placed a purchase order for a 300 kW PEM electrolyzer and associated balance of plant equipment.
  • The system will use Fusion Fuel’s plug-and-play HEVO-Chain technology, which employs a building-block approach using modular 20 kW Cubes to deliver green hydrogen solutions tailored to individual customer needs.
  • The project, which will be developed in Spain, is expected to be fully installed and operational in the first half of 2024.
  • With Fusion Fuel’s oxygen capture system, the client can now further reduce its environmental impact by harnessing this oxygen for other applications.

Banyan Security Introduces Groundbreaking Zero Trust Clientless Solution for Secure Remote Access in the Healthcare Industry

Retrieved on: 
Tuesday, September 26, 2023
IBM, Workflow, Electronic health record, EMR, Health care, Physician, Cerner, Allscripts, Nursing, Risk, SAN, EHR, Banyan, Office of Enforcement and Compliance Assurance, Health, HIPAA, Medical device, Hospital, Construction, Online shopping, Fusion

Banyan Security recognizes these challenges and has risen to the occasion with its state-of-the-art Zero Trust Clientless solution, providing unparalleled security and compliance capabilities.

Key Points: 
  • Banyan Security recognizes these challenges and has risen to the occasion with its state-of-the-art Zero Trust Clientless solution, providing unparalleled security and compliance capabilities.
  • "Banyan Security is committed to addressing the unique security and access challenges faced by the healthcare industry," stated Bert Rankin, Chief Marketing Officer at Banyan Security.
  • "Our Clientless Zero Trust solution represents a new era of secure access, enabling healthcare organizations to facilitate seamless collaboration while upholding patient data protection and regulatory compliance."
  • For more information about Banyan Security's Zero Trust Clientless solution and how it is transforming secure access in the healthcare industry, visit [ www.Banyansecurity.io ]

Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences

Retrieved on: 
Tuesday, September 5, 2023
Webcast, Morgan, Conference, Fusion

HAMILTON, ON and BOSTON, Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences.

Key Points: 
  • HAMILTON, ON and BOSTON, Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences.
  • The H.C. Wainwright 25th Annual Global Investment Conference – The Company presentation will take place on Tuesday, September 12, 2023 at 2:00 p.m.
  • Presenting on behalf of Fusion will be Chief Financial Officer John Crowley.
  • A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.